Experimental isolation and transplantation of hepatocytes with the use of antibody against interleukin-2 receptor (daclizumab) as immunosuppressive agent

Απλή σελίδα τεκμηρίου
dc.contributor.authorTsiolis, I.en
dc.contributor.authorPapalois, A.en
dc.contributor.authorLoukopoulos, I.en
dc.contributor.authorGravvanis, A.en
dc.contributor.authorLykoudis, E.en
dc.contributor.authorTheodossopoulou, E.en
dc.contributor.authorChairakakis, A.en
dc.contributor.authorDimitroulopoulos, D.en
dc.contributor.authorSfiniadakis, I.en
dc.contributor.authorVassiliou, I.en
dc.contributor.authorFelekouras, E.en
dc.contributor.authorDedeilias, P.en
dc.contributor.authorKontogiorgi, M.en
dc.contributor.authorPapadimitriou, L.en
dc.contributor.authorPapadimitriou, I.en
dc.date.accessioned2015-11-24T19:16:58Z
dc.date.available2015-11-24T19:16:58Z
dc.identifier.issn0041-1345-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21729
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectAntibodies, Monoclonal/*therapeutic useen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectGraft Survivalen
dc.subjectHepatocytes/*cytology/*transplantationen
dc.subjectImmunoglobulin G/*therapeutic useen
dc.subjectImmunosuppressive Agents/*therapeutic useen
dc.subjectLiver Failure, Acute/*surgeryen
dc.subjectMaleen
dc.subjectModels, Animalen
dc.subjectRatsen
dc.subjectRats, Inbred Lewen
dc.subjectRats, Wistaren
dc.subjectReceptors, Interleukin-2/immunologyen
dc.subjectSpleenen
dc.subjectTransplantation, Homologous/*immunologyen
dc.titleExperimental isolation and transplantation of hepatocytes with the use of antibody against interleukin-2 receptor (daclizumab) as immunosuppressive agenten
heal.abstractINTRODUCTION: Daclizumab (Dmab) is a genetically engineered humanized IgG1 monoclonal antibody that binds to the alpha chain of the interleukin-2 receptor (Tac, CD25, p55) expressed on activated human T lymphocytes. Dmab has been used in a clinical protocol of islet transplantation with satisfactory results. The aim of the present study was to evaluate the use of an antibody against the interleukin-2 receptor (Dmab) as an immunosuppressive agent in an experimental model of hepatocyte allotransplantation (allo-Tx) in rats with fulminant hepatic failure (FHF). MATERIALS AND METHODS: Six Wistar rats were used as donors and 48 Lewis rats as recipients: four groups of 12 animals each with induction of FHF and 24 hour later hepatocyte Tx--group A: no treatment; group B: cyclosporin (20 mg/kg days 0 to 5 and 10 mg/kg days 6 to 15); group C: Dmab (0.05 mg day of Tx and 0.05 mg day 7); and group D: Dmab and cyclosporine. Hepatocytes were transplanted intrasplenically. Animals were followed for 15 days. RESULTS: Statistical analysis showed better survival among groups C (83%, MST = 13) and D (92%, MST = 14.25) compared to groups A (max 72, MST = 1.5) or B (50%, MST = 9). Survival in group D was better but not significantly than group C. Biochemical evaluation and histology confirmed satisfactory function and engraftment, respectively. CONCLUSION: This experimental model showed the safe, effective use of Dmab.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.transproceed.2005.02.097-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15919507-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0041134505002137/1-s2.0-S0041134505002137-main.pdf?_tid=6c7f5e0f151836aebe43c26e30efa7b9&acdnat=1333466359_a0997b78a318651a2cc299834eb56de3-
heal.journalNameTransplant Procen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ